Opinion

Video

Bladder Cancer: Highlights from ESMO 2023 and Ongoing Developments

Author(s):

Axel Merseburger, MD, PhD,M. Carmen Mir, MD, PhD

The expert panel reviews highlights from ESMO 2023 and discusses ongoing developments in the treatment landscape for bladder cancer.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected
    Related Videos
    Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
    Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
    Joshua J. Meeks, MD, PhD, answers a question during a Zoom video interview
    Joshua J. Meeks, MD, PhD, discusses NIAGARA data for patient undergoing cystectomy
    Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
    Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
    Study data point to gender disparities in oncology research citations
    Study data point to gender disparities in oncology research citations
    Matthew Galsky, MD, on patient selection for perioperative durvalumab/chemo in MIBC
    Matthew Galsky, MD, on patient selection for perioperative durvalumab/chemo in MIBC
    Suzanne B. Merrill, MD, FACS, answers a question during a Zoom video interview
    Suzanne B. Merrill, MD, FACS, discusses rBCG and the NMIBC landscape
    Urinary bladder | Image Credit: © magicmine - stock.adobe.com
    Expert describes implications of neoadjuvant durvalumab approval in MIBC
    Sima Porten, MD, on gene-environment interactions in bladder cancer development
    Sima Porten, MD, on gene-environment interactions in bladder cancer development
    3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
    How rBCG EAP could open up access for Anktiva in bladder cancer
    Betty Wang, MD, discusses studies from the 2025 EAU meeting
    Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
    Related Content
    FDA issues refusal to file letter on sBLA for nogapendekin alfa inbakicept
    May 5th 2025

    FDA issues refusal to file letter on sBLA for nogapendekin alfa inbakicept

    Hannah Clarke
    The sBLA for NAI was submitted to the FDA in March 2025.
    Dr. Schwen on focal therapies for prostate cancer
    January 11th 2024

    Dr. Schwen on focal therapies for prostate cancer

    Cleveland Clinic
    Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
    Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
    April 29th 2025

    Cxbladder Triage may help patients avoid unnecessary cystoscopies

    Benjamin P. Saylor
    The study population was able to avoid 952 cystoscopies and 71 CT scans, according to the investigators.
    medical depiction of bladder cancer
    May 31st 2023

    Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

    Urology Times staff
    In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
    Sandip M. Prasad, MD, MPhil
    April 27th 2025

    UGN-102 positions itself as an alternative to TURBT for low-grade NMIBC

    Benjamin P. Saylor
    "I would argue that UGN-102 may very well represent a well-tolerated alternative to TURBT as primary treatment for patients with low-grade disease,” says Sandip M. Prasad, MD, MPhil.
    Blur image of hospital corridor | Image Credit: © jakkapan - stock.adobe.com
    April 27th 2025

    Estimated DOR of 2 years is seen with UGN-102 in LG-IR-NMIBC

    Benjamin P. Saylor
    The investigators reported that the median Kaplan-Meier estimate of DOR was 24.2 months.
    © 2025 MJH Life Sciences

    All rights reserved.